Moreover, the 36-month beta value for NVAX is 2.04. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NVAX is 153.00M and currently, short sellers hold a 26.00% of that float. On December 24, 2024, NVAX’s average trading volume was 5.69M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NVAX) stock’s latest price update
Novavax, Inc (NASDAQ: NVAX)’s stock price has gone decline by -0.93 in comparison to its previous close of 8.64, however, the company has experienced a -4.89% decrease in its stock price over the last five trading days. zacks.com reported 2024-12-24 that Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
NVAX’s Market Performance
Novavax, Inc (NVAX) has experienced a -4.89% fall in stock performance for the past week, with a 1.06% rise in the past month, and a -28.90% drop in the past quarter. The volatility ratio for the week is 5.24%, and the volatility levels for the past 30 days are at 5.92% for NVAX. The simple moving average for the past 20 days is -2.19% for NVAX’s stock, with a -18.81% simple moving average for the past 200 days.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with JP Morgan repeating the rating for NVAX by listing it as a “Underweight.” The predicted price for NVAX in the upcoming period, according to JP Morgan is $8 based on the research report published on July 30, 2024 of the current year 2024.
BofA Securities gave a rating of “Neutral” to NVAX, setting the target price at $12 in the report published on May 10th of the current year.
NVAX Trading at -5.41% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.12% of loss for the given period.
Volatility was left at 5.92%, however, over the last 30 days, the volatility rate increased by 5.24%, as shares sank -8.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.34% lower at present.
During the last 5 trading sessions, NVAX fell by -5.33%, which changed the moving average for the period of 200-days by +66.45% in comparison to the 20-day moving average, which settled at $8.75. In addition, Novavax, Inc saw 78.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVAX starting from Rachel K. King, who proposed sale 4,150 shares at the price of $9.00 back on Dec 13 ’24. After this action, Rachel K. King now owns shares of Novavax, Inc, valued at $37,350 using the latest closing price.
Dubovsky Filip, the Officer of Novavax, Inc, proposed sale 7,335 shares at $13.00 during a trade that took place back on Sep 18 ’24, which means that Dubovsky Filip is holding shares at $95,331 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -0.33 for the present operating margin
- 0.67 for the gross margin
The net margin for Novavax, Inc stands at -0.32. The total capital return value is set at -0.56.
Based on Novavax, Inc (NVAX), the company’s capital structure generated -0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.54. The debt to equity ratio resting at -0.32. The interest coverage ratio of the stock is -17.78.
Currently, EBITDA for the company is -487.39 million with net debt to EBITDA at 1.57. When we switch over and look at the enterprise to sales, we see a ratio of 1.17. The receivables turnover for the company is 9.32for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.93.
Conclusion
To wrap up, the performance of Novavax, Inc (NVAX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
